What Happened

Noucor, a Spain-based international healthcare group backed by MCH Private Equity, has completed its acquisition of Helm Pharmaceuticals, a German developer of finished dosage form pharmaceutical products. The seller was Helm AG, one of the largest independent chemical companies in the world. Financial terms were not disclosed.

Helm divested as part of its strategy to focus on core markets and growth priorities. Noucor said the acquisition strengthens its capabilities across product development, regulatory affairs, supply chain management, commercial operations, and lifecycle management.

Who Is Affected

Noucor and Helm Pharmaceuticals are the primary parties: Noucor gains Helm's finished-dosage portfolio, market positions across multiple therapeutic categories, operating platform, and team. Noucor is now expected to reach approximately €200m (US$225m) in revenue by the end of 2026.

Helm AG exits pharma finished-dose ownership, while MCH Private Equity, which invested in Noucor in December 2021, gains a larger platform for further European expansion.

Market Impact

The deal is part of a broader consolidation trend in European pharma and healthcare logistics, with Noucor explicitly signaling ambitions to build one of Europe's most respected pharmaceutical platforms.

• Noucor expects to cross €200m revenue by end of 2026, scale that will require integrated compliance, QA, and commercial systems.
• Carve-out from Helm AG means Noucor must stand up independent operational infrastructure for regulatory affairs and supply chain.
• Advisers on the transaction include Société Générale, PwC, Jefferies, Freshfields, Garrigues, Gleiss Lutz, and KPMG, indicating a complex cross-border carve-out.

What to Watch

Watch for post-close integration decisions from Noucor's leadership team, particularly around systems consolidation, regulatory filings, and supplier contracts tied to Helm Pharmaceuticals' finished-dose operations.

Noucor's CEO David Perdigó called the deal "just the beginning," so further acquisitions in the European pharma platform strategy are likely. That creates additional M&A-related sales triggers for vendors serving life sciences companies.

Related coverage

• Ambrose Healthcare acquires AM-Pharma for up to €161M, gaining European base
• Merck KGaA to acquire UK biotech Silence Therapeutics in $1.3bn RNA deal
• Mankind Pharma acquires 70% stake in Belgium CAR-T biotech ACTx for €48M
• STERIS agrees to acquire surgical safety firm Xodus Medical for $2.1B